Welcure Drugs & Pharmaceuticals Intrinsic Value
Welcure Drugs & Pharmaceuticals (WELCURE) median intrinsic value is ₹0.62 from 2 valuation models (range ₹1–₹1), vs current price ₹0.25 — +148.0% upside (Trading Below Calculated Value), margin of safety 59.7%. Analyse WELCURE promoter holding to track promoter, FII and institutional holdings.
WELCURE Valuation Methods Summary — DCF, Graham Number & P/E
Welcure Drugs & Pharmaceuticals intrinsic value across 2 models vs current price ₹0.25 — upside/downside and value range per method. Read WELCURE dividend yield for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹0.62 | ₹0.56 - ₹0.68 | +148.0% | Book Value/Share: ₹7.82, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹0.50 | ₹0.45 - ₹0.55 | +100.0% | Revenue/Share: ₹29.52, P/S: 2.0x |
WELCURE Intrinsic Value vs Market Price — All Valuation Models
Welcure Drugs & Pharmaceuticals fair value range ₹1–₹1 vs current market price ₹0.25 across 2 valuation models. For current market price and key ratios, visit Welcure Drugs & Pharmaceutical stock price NSE.
WELCURE Intrinsic Value Analysis — Undervalued or Overvalued?
Welcure Drugs & Pharmaceuticals median intrinsic value ₹0.62, current price ₹0.25 — Trading Below Calculated Value by 148.0%, margin of safety 59.7%.
What is the intrinsic value of WELCURE?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Welcure Drugs & Pharmaceuticals (WELCURE) is ₹0.62 (median value). With the current market price of ₹0.25, this represents a +148.0% variance from our estimated fair value.
The valuation range spans from ₹0.50 to ₹0.62, indicating ₹0.50 - ₹0.62.
Is WELCURE undervalued or overvalued?
Based on our multi-method analysis, Welcure Drugs & Pharmaceuticals (WELCURE) appears to be trading below calculated value by approximately 148.0%.
WELCURE Financial Health — Key Ratios vs Industry Benchmarks
Welcure Drugs & Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | -5.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.72x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
WELCURE Cash Flow Quality — Operating & Free Cash Flow
Welcure Drugs & Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-222 Cr | ₹-222 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |